Sandip M. Prasad, William C. Huang, Neal D. Shore, Brian Hu, Marc Bjurlin, Gordon A. Brown, Pencho Genov, Dimitar Shishkov, Alexandre Khuskivadze, T. Ganev, Dobri Marchev, Igor Orlov, E. Kopyltsov, Vadim Zubarev, Alexander Nosov, Dmitrii Komlev, Brent Burger, Sunil Raju, Andrew Meads, M. Schoenberg
{"title":"用 ugn-102 和经尿道膀胱肿瘤切除术(turbt)治疗低度中危非肌浸润性膀胱癌与单用 turbt 治疗相比:Atlas 3 期试验","authors":"Sandip M. Prasad, William C. Huang, Neal D. Shore, Brian Hu, Marc Bjurlin, Gordon A. Brown, Pencho Genov, Dimitar Shishkov, Alexandre Khuskivadze, T. Ganev, Dobri Marchev, Igor Orlov, E. Kopyltsov, Vadim Zubarev, Alexander Nosov, Dmitrii Komlev, Brent Burger, Sunil Raju, Andrew Meads, M. Schoenberg","doi":"10.1016/j.urolonc.2024.01.170","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":506909,"journal":{"name":"Urologic Oncology: Seminars and Original Investigations","volume":"34 S2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NONMUSCLE-INVASIVE BLADDER CANCER WITH UGN-102 ± TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) COMPARED TO TURBT MONOTHERAPY: THE PHASE 3 ATLAS TRIAL\",\"authors\":\"Sandip M. Prasad, William C. Huang, Neal D. Shore, Brian Hu, Marc Bjurlin, Gordon A. Brown, Pencho Genov, Dimitar Shishkov, Alexandre Khuskivadze, T. Ganev, Dobri Marchev, Igor Orlov, E. Kopyltsov, Vadim Zubarev, Alexander Nosov, Dmitrii Komlev, Brent Burger, Sunil Raju, Andrew Meads, M. Schoenberg\",\"doi\":\"10.1016/j.urolonc.2024.01.170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":506909,\"journal\":{\"name\":\"Urologic Oncology: Seminars and Original Investigations\",\"volume\":\"34 S2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology: Seminars and Original Investigations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2024.01.170\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology: Seminars and Original Investigations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2024.01.170","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NONMUSCLE-INVASIVE BLADDER CANCER WITH UGN-102 ± TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) COMPARED TO TURBT MONOTHERAPY: THE PHASE 3 ATLAS TRIAL